Literature DB >> 7779528

Indium-111 antimyosin monoclonal antibody Fab imaging in patients with cardiomyopathy.

M Ishibashi1, T Wada, S Morita, Y Koga, S Tanaka, N Umezaki, H Toshima, N Hayabuchi.   

Abstract

Six patients with cardiomyopathy were imaged following intravenous injection of an indium-111 labeled monoclonal antibody directed against the heavy chain of cardiac myosin. Two patients had hypertrophic non-obstructive cardiomyopathy (HNCM), two patients had dilated cardiomyopathy (DCM), and two patients had specific heart muscle disease. One of 2 patients with HNCM and one of 2 patients with DCM had a positive antimyosin scan. The 2 patients with specific heart muscle disease manifested persistent blood pool activity of the antibody, thereby precluding interpretation of the images. The present report demonstrates that antimyosin antibody imaging may provide evidence of myocardial injury, or necrosis in some patients with cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7779528     DOI: 10.1007/bf03165006

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  23 in total

1.  Myocardial uptake of indium-111-labeled antimyosin in acute subendocardial infarction: clinical, histochemical, and autoradiographic correlation of myocardial necrosis.

Authors:  R C Hendel; B A McSherry; J A Leppo
Journal:  J Nucl Med       Date:  1990-11       Impact factor: 10.057

2.  Indium-111 antimyosin scintigraphy to assess myocardial damage in patients with suspected myocarditis and cardiac rejection.

Authors:  I Carrió; L Berná; M Ballester; M Estorch; D Obrador; M Cladellas; L Abadal; M Ginjaume
Journal:  J Nucl Med       Date:  1988-12       Impact factor: 10.057

3.  High prevalence of myocardial monoclonal antimyosin antibody uptake in patients with chronic idiopathic dilated cardiomyopathy.

Authors:  D Obrador; M Ballester; I Carrió; L Bernà; G Pons-Lladó
Journal:  J Am Coll Cardiol       Date:  1989-05       Impact factor: 24.094

4.  Myocardial damage delineated by indium-111 antimyosin Fab and technetium-99m pyrophosphate.

Authors:  B A Khaw; H W Strauss; R Moore; J T Fallon; T Yasuda; H K Gold; E Haber
Journal:  J Nucl Med       Date:  1987-01       Impact factor: 10.057

5.  Localization of radiolabeled cardiac myosin-specific antibody in myocardial infarcts. Comparison with technetium-99m stannous pyrophosphate.

Authors:  G A Beller; B A Khaw; E Haber; T W Smith
Journal:  Circulation       Date:  1977-01       Impact factor: 29.690

6.  Acute myocardial infarct imaging with indium-111-labeled monoclonal antimyosin Fab.

Authors:  B A Khaw; T Yasuda; H K Gold; R C Leinbach; J A Johns; M Kanke; M Barlai-Kovach; H W Strauss; E Haber
Journal:  J Nucl Med       Date:  1987-11       Impact factor: 10.057

7.  Indium 111-monoclonal antimyosin antibody imaging in the diagnosis of acute myocarditis.

Authors:  T Yasuda; I F Palacios; G W Dec; J T Fallon; H K Gold; R C Leinbach; H W Strauss; B A Khaw; E Haber
Journal:  Circulation       Date:  1987-08       Impact factor: 29.690

8.  Myocardial infarct imaging of antibodies to canine cardiac myosin with indium-111-diethylenetriamine pentaacetic acid.

Authors:  B A Khaw; F T Fallon; H W Strauss; E Haber
Journal:  Science       Date:  1980-07-11       Impact factor: 47.728

9.  Early imaging of experimental myocardial infarction by intracoronary administraion of 131I-labelled anticardiac myosin (Fab')2 fragments.

Authors:  B A Khaw; H K Gold; R C Leinbach; J T Fallon; W Strauss; G M Pohost; E Haber
Journal:  Circulation       Date:  1978-12       Impact factor: 29.690

10.  Measurement of infarct size and percentage myocardium infarcted in a dog preparation with single photon-emission computed tomography, thallium-201, and indium 111-monoclonal antimyosin Fab.

Authors:  L L Johnson; K S Lerrick; J Coromilas; D W Seldin; P D Esser; J M Zimmerman; A M Keller; P O Alderson; J T Bigger; P J Cannon
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.